Regression of Human Breast Tumor Xenografts in Response to (E)-2’-Deoxy-2’-(fluoromethylene)cytidine, an Inhibitor of Ribonucleoside Diphosphate Reductase

Cancer Research

Volumn 54, Issue 6, 1994, Pages 1485-1490

  Bitonti, Alan J ^a   Dumont, Jennifer A ^a   Bush, Tammy L ^a   Cashman, Elizabeth A ^a   Cross Doersen, Doreen E ^a   Wright, Paul S ^a   Matthews, Donald P ^a   McCarthy, James R ^a   Kaplan, Donald A ^a  

^a Merrell Dow Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DERIVATIVE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL DEATH; CELL DIVISION; DEOXYCYTIDINE; ESTROGENS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0028210794     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Elford, H.L., Freese, M., Passamani, E., and Morris, H.P. Ribonucleotide reductase and cell proliferation. J. Biol. Chem., 245: 5228-5233, 1970.
2. Elford, H.L. Functional regulation of mammalian ribonucleotide reductase. In: G. Weber (ed.), Advances in Enzyme Regulation, pp. 19-38, New York: Pergamon Press, Ltd., 1972.
3. Elford, H.L. Effect of hydroxyurea on ribonucleotide reductase. Biochem. Biophys. Res. Commun., 33: 129-135, 1968.
4. Donehower, R.C. Hydroxyurea. In: B.A. Chabner and J.M. Collins (eds.), Cancer Chemotherapy: Principles and Practice, pp. 225-233. Philadelphia: J.B. Lippincott Co., 1990.
5. Hertel, L.W., Kroin, J.S., Misner, J.W., and Tustin, J.M. Synthesis of 2-deoxy-2, 2-difluoro-D-ribose and 2-deoxy-2, 2-difluoro-D-ribofuranosyl nucleosides. J. Org. Chem., 53: 2406-2409, 1988.
6. Baker, C.H., Bollinger, J.M., Stubbe, J., Samano, V., Robins, M.J., Lippert, B., Jarvi, E., and Resvick, R. 2′-Deoxy-2′-methylencytidine and 2′-deoxy-2′,2′-difluorocyti-dine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem., 34: 1879-1884, 1991.
7. Takenuki, K., Matsuda, A., Ueda, T., Sasaki, T., Fujii, A., and Yamagami, K. Design, synthesis and antineoplastic activity of 2′-deoxy-2′-methylidene-cytidine. J. Med. Chem., 31: 1063-1064, 1988.
8. Elford, H.L., and Van't Riet, B. Inhibition of nucleoside diphosphate reductase by hydrobenzolhydroxamic acid derivatives. Pharmacol. Ther., 29: 239-245, 1985.
9. McCarthy, J.R., Matthews, D.P., Stemerick, D.M., Huber, E.W., Bey, P., Lippert, B.J., Snyder, R.D., and Sunkara, P.S. Stereospecific method to E and Z terminal fluoro olefins and its application to the synthesis of 2′-deoxy-2′-fluoromethylene nucleosides as potential inhibitors of ribonucleoside diphosphate reductase. J. Am. Chem. Soc., 113: 7439-7440, 1991.
10. Grindey, G.B., Hertel, L.W., and Plunkett, W. Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycytidlne (gemcitabine). Cancer Invest., 8: 313, 1990.
11. Rubens, R.D., Kaye, S.B., Soukop, M., Williams, C.J., Brampton, M.H., and Harris, A.L. Phase II trial of didox in advanced breast cancer. Br. J. Cancer, 64: 1187-1188, 1991.
12. Cannichael, J., Philip, P., Rea, D., Kerr, H., Walling, J., Harris, A.L., and Possinger, K. Gemcitabine: an active drug in advanced breast cancer. Results of a Phase II study. Proc. Am. Soc. Clin. Oncol., 11: 136, 1992.
13. Harris, J.R., Lippman, M.E., Veronesi, U., and Willett, W. Breast Cancer. N. Engl. J. Med., 327: 319-328, 390-398, 473-480, 1992.
14. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339: 1-15, 71-85, 1992.
15. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S., and Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
16. Houchens, D.P., Ovejera, A.A., and Barker, A.D. The therapy of human tumors in athymic (nude) mice. In: D.P. Houchens and A.A. Ovejera (eds.), Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research, pp. 267-280. New York: Gustav Fischer New York, Inc., 1977.
17. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
18. Hertel, L.W., Boder, G.B., Kroin, J.S., Rinzel, S.M., Poore, G.A., Todd, G.C., and Grindey, G.B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res., 50: 4417-4422, 1990.
19. Plunkett, W., Gandhi, V., Chubb, S., Nowak, B., Heinemann, V., Mineishi, S., Sen, A., Hertel, L.W., and Grindey, G.B. 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides, 8: 775-785, 1989.
20. Fox, R.M. Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase. Pharmacol. Ther., 30: 31-42, 1993.
21. Heinemann, V., Xu, Y.Z., Chubb, S., Sen, A., Hertel, L.W., Grindey, G.B., and Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol., 38: 567-572, 1990.
22. Eriksson, S., Gräslund, A., Skog, S., Thelander, L., and Tribukait, B. Cell cycle-dependent regulation of mammalian ribonucleotde reductase. J. Biol. Chem., 259: 11695-11700, 1984.
23. Eriksson, S., and Martin, D.W., Jr. Ribonucleotide reductase in cultured mouse lymphoma cells. J. Biol. Chem., 256: 9436-9440, 1981.
24. Wyllie, A.H., Kerr, J.F., and Currie, A.R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251-306, 1980.
25. Barry, M.A., Behnke, C.A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
26. Dive, C., and Hickman, J.A. Drug target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64: 192-196, 1991.
27. Johnson, C.A., Förster, T.H., Winterford, C.M., and Allan, D.J. Hydroxyurea induces apoptosis and regular DNA fragmentation in a Burkitt's lymphoma cell line. Biochim. Biophys. Acta, 1136: 1-4, 1992.
28. Gorczyca, W., Bruno, S., Darzynkiewicz, R.J., Gong, J., and Darzynkiewicz, Z. DNA strand breaks occurring during apoptosis: their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int. J. Oncol., 1: 639-648, 1992.
29. Gorczyca, W., Gong, J., and Darzynkiewicz, Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res., 53: 1945-1951, 1993.